Natera
Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests
Guardant has asked the court to recover damages and to prevent Natera from further disseminating "deceptive" advertising regarding their competing assays.
Invitae Sues Natera Alleging Infringement of Patent on DNA Sequencing Assembly Technique
Invitae believes its '799 patent improves upon prior art and wants a US District Court to find that Natera is infringing its IP with its Signatera test.
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
Personalis Q1 Revenues Grow 9 Percent
The firm tallied $20.9 million in revenues compared to $19.2 million a year ago, edging analysts' consensus estimate of $20.4 million.
Medicare Administrative Contractor Palmetto Finalizes Coverage of Molecular Testing for Organ Transplant Rejection
Under the policy, covered tests must provide information about active rejection status or cellular or antibody-mediated rejection status.